Survival Experience Following Nd:YAG Laser Photoresection for Primary Bronchogenic Carcinoma: Survival Estimates The 58 patients in the control group (42 males, 16 females; squamous cell = 33, large cell = 17, adenocarcinoma = 8) received a median dose of 5,000 rads. All patients in this group were dead at time of last follow-up. Even though the median survival with combined modalities (XRT + YPR) appears to be better than conventional XRT alone (304 vs 253 days), the overall survival distribution of these two groups were not statistically significantly different (p = 0.17; Fig 2). Figure 3 compares the survival distributions from zero time of patients with NSCLC who underwent conventional XRT (control group) to those treated with combined modalities (XRT+YPR) by histopathologic cell type. The differences between the survival distributions of these four groups were not statistically significant (p = 0.51). There does not appear to be a separation either by treatment group or by cell type.

Table 3 examines the survival distributions from zero time of the control group and of patients with NSCLC undergoing XRT and YPR both with and without the presence of metastatic disease. Within metastatic disease status, the survival distributions of the two treatment groups did not differ significantly. Figure 4 compares the survival distributions of patients who received initial XRT for inoperable NSCLC who later became symptomatic and underwent YPR (n = 20; median survival, 312 days) with patients in the control group who had inoperable NSCLC who underwent routine conventional XRT on a nonurgent basis (n = 47; median survival, 258 days). The survival distributions of these two groups were not statistically significantly different (p = 0.44).
The survival experiences of patients who underwent emergency YPR (n = 15; median survival, 267 days) were significantly better (p = 0.04) than those who underwent only emergency XRT (n = 11; median survival, 150 days). These distributions are demonstrated in Figure 5.
Table 3—Survival Estimates by Treatment Groups and Metastatic Disease Status

TimeSince

Diagnosis

XRT Alone (Control Group) XRT + YPR
No. Surv Est, % SE,% No. Surv Est, % SE,%
Metastases present
0 19 100.0 10 100.0
4 mo 15 78.9 9.0 5 50.0 16.0
6 mo 10 52.6 11.0 5 50.0 16.0
lyr 4 21.1 9.0 2 20.0 13.0
2 yr 1 5.3 5.0 2 20.0 13.0
Median survival 248.0 days 125.0 days
Mean survival 272.9 days 157.8 days
Log rank test p value = 0.84
Metastases absent
0 39 100.0 25 100.0
4 mo 29 74.4 7.0 22 88.0 7.0
6 mo 25 64.1 8.0 19 76.0 9.0
lyr 14 35.9 8.0 11 47.7 10.0
2 yr 8 20.5 6.0 3 20.2 9.0
Median survival 256.0 days 363.0 days
Mean survival 395.6 days 491.6 days
Log rank test p value = 0.33

 

Figure 2. Survival estimates by treatment groups in patients with non-small cell primary bronchogenic carcinoma.

Figure 2. Survival estimates by treatment groups in patients with non-small cell primary bronchogenic carcinoma.

Figure 3. Survival estimates by treatment group and cell type.

Figure 3. Survival estimates by treatment group and cell type.

Figure 4. Survival estimates in patients undergoing nonurgent palliative treatment

Figure 4. Survival estimates in patients undergoing nonurgent palliative treatment

Figure 5. Survival estimates in patients undergoing emergency palliative treatment

Figure 5. Survival estimates in patients undergoing emergency palliative treatment